However, the high sequence similarity between ARID1B and ARID1A and the association of ARID1B loss with intellectual disability syndromes[70] pose challenges for the development of small‐molecule inhibitors that are selectively ARID1B‐specific and can be precisely delivered to affected tissues. This evidence concerns the gene ARID1A and syndromic intellectual disability.